CTOs on the Move


 
Acorda Therapeutics is a publicly traded (NASDAQ: ACOR) biotechnology company whose mission is to develop therapies that restore neurological function and improve the lives of people with neurological disorders. We started our company in 1995 as a network of scientists, physicians and business people with a common belief that sharing ideas and information could lead to innovative medical advances for people with neurological disorders. We have since evolved into a commercial-stage biotechnology company, successfully developing and commercializing important therapies that advance the care of people affected by neurological conditions. We achieve our goals by: • investing in research and development ...
  • Number of Employees: 250-1000
  • Annual Revenue: $500M-1 Billion
  • www.acorda.com
  • 420 Saw Mill River Road
    Ardsley, NY USA 10502
  • Phone: 800.367.5109

Executives

Name Title Contact Details

Similar Companies

Intralytix

Intralytix, Inc. is a biotechnology company focused on the production and marketing of bacteriophage-based products to control bacterial pathogens in environmental, food processing, and medical settings.

Kai Pharmaceuticals

Kai Pharmaceuticals is a South San Francisco, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Bayer Healthcare Pharmacuticals

Committed to developing novel diagnostics and therapeutics that address unmet medical needs, Berlex, Inc., a U.S. affiliate of Schering AG, Germany (NYSE:SHR), develops and markets diagnostic imaging agents, treatments in the areas of female healthcare

Finch Therapeutics

Finch Therapeutics is a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery platform to develop a novel class of orally administered biological drugs. With the capabilities to develop both complete and targeted microbiome therapeutics, Finch is advancing a rich pipeline of candidates designed to address a wide range of unmet medical needs. Finch`s lead candidate, CP101, is in late-stage clinical development for recurrent C. difficile infection (CDI). In June 2020, Finch announced that CP101 met its primary efficacy endpoint in PRISM3, the first of two pivotal trials to support the development of CP101 for the prevention of recurrent CDI. Finch is also developing CP101 for chronic hepatitis B, and FIN-211 for autism spectrum disorder. In partnership with Takeda, Finch is advancing FIN-524 and FIN-525 for ulcerative colitis and Crohn`s disease, respectively.

Kyowa Pharmaceutical

Kyowa Pharmaceutical is a Princeton, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.